person · Reporting owner
Toernsen Monika Maria
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IMMUNIC, INC.IMUX · Entity 6306 | Director | June 05, 2025 | June 09, 2025 |
| Passage BIO, Inc.PASG · Entity 7829 | Chief Commercial Officer | September 15, 2022 | November 18, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IMMUNIC, INC.
Report date June 05, 2025 · Filed June 09, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.77 · Expires 2035-06-05 | Direct | 150,000 |
Reported balance
After 2025-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-05 · Grant · Acquired 150,000 · Balance 150,000 F1: The option vests in monthly increments over a period of one year from the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in monthly increments over a period of one year from the grant date.
Passage BIO, Inc.
Report date September 15, 2022 · Filed November 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,319 |
Ending reported balance
After 2022-09-19 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-09-15 · Exercise / conversion · Acquired 5,000 · Balance 5,000 F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Row 2 · 2022-09-19 · Sale · Disposed 1,681 · Balance 3,319 F2: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2031-07-18 | Direct | 15,000 |
Reported balance
After 2022-09-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-09-15 · Exercise / conversion · Disposed 5,000 · Balance 15,000 F3: Each RSU represents a contingent right to receive one share of Issuer's common stock. F4: 1/4 of the RSUs vested on September 15, 2022, and the remainder will vest as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F3: Each RSU represents a contingent right to receive one share of Issuer's common stock.
F4: 1/4 of the RSUs vested on September 15, 2022, and the remainder will vest as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2025 Filed Jun 9, 2025 16:07 UTC | IMMUNIC, INC. IMUX · Entity 6306 | GrantStock Option · Derivative | 150,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001193805-25-000840 · e664609_4-toernsen.xml · derivative · entry 1 Toernsen Monika Maria · CIK 0001873385 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2035-06-05 F1 · derivative.exercise_date: The option vests in monthly increments over a period of one year from the grant date. Read SEC document |
| June 11, 2024 Filed Jun 12, 2024 16:05 UTC | IMMUNIC, INC. IMUX · Entity 6306 | GrantStock Option · Derivative | 100,000 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001193805-24-000785 · e663704_4-toernsen.xml · derivative · entry 1 Toernsen Monika Maria · CIK 0001873385 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-06-11 F1 · derivative.exercise_date: The option vests in monthly increments over a period of one year from the grant date. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 21:50 UTC | IMMUNIC, INC. IMUX · Entity 6306 | GrantStock Option · Derivative | 30,000 | Not disclosed Strike: $1.72 | Not disclosed |
DisclosureSEC source: 0001193805-24-000318 · e619332_4-toernsen.xml · derivative · entry 2 Toernsen Monika Maria · CIK 0001873385 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-07-18 F1 · derivative.exercise_price: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date. F1 · price: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date. F1 · derivative.exercise_date: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 21:50 UTC | IMMUNIC, INC. IMUX · Entity 6306 | Disposition to issuerStock Option · Derivative | 30,000 | Not disclosed Strike: $4.30 | Not disclosed |
DisclosureSEC source: 0001193805-24-000318 · e619332_4-toernsen.xml · derivative · entry 1 Toernsen Monika Maria · CIK 0001873385 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2031-07-18 F1 · derivative.exercise_price: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date. F1 · price: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date. F1 · derivative.exercise_date: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date. Read SEC document |
| June 28, 2023 Filed Jun 29, 2023 16:36 UTC | IMMUNIC, INC. IMUX · Entity 6306 | GrantStock Option · Derivative | 16,000 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001193805-23-000915 · e618742_4-toernsen.xml · derivative · entry 1 Toernsen Monika Maria · CIK 0001873385 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2033-06-28 F1 · derivative.exercise_date: The option vests in monthly increments over a period of one year from the grant date. Read SEC document |
| September 19, 2022 Filed Nov 18, 2022 17:01 UTC | Passage BIO, Inc. PASG · Entity 7829 | SaleCommon Stock | 1,681 | $1.51 | $2,539.15 |
DisclosureSEC source: 0001209191-22-057891 · doc4.xml · nonDerivative · entry 2 Toernsen Monika Maria · CIK 0001873385 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,319 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| September 15, 2022 Filed Nov 18, 2022 17:01 UTC | Passage BIO, Inc. PASG · Entity 7829 | Exercise / conversionRestricted Stock Unit · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-057891 · doc4.xml · derivative · entry 3 Toernsen Monika Maria · CIK 0001873385 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 5,000 shares Expires 2031-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: 1/4 of the RSUs vested on September 15, 2022, and the remainder will vest as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| September 15, 2022 Filed Nov 18, 2022 17:01 UTC | Passage BIO, Inc. PASG · Entity 7829 | Exercise / conversionCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-057891 · doc4.xml · nonDerivative · entry 1 Toernsen Monika Maria · CIK 0001873385 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| July 08, 2022 Filed Jul 11, 2022 16:07 UTC | IMMUNIC, INC. IMUX · Entity 6306 | GrantStock Option · Derivative | 30,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001193805-22-001090 · e621829_4-toernsen.xml · derivative · entry 1 Toernsen Monika Maria · CIK 0001873385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-07-08 F1 · derivative.exercise_date: 10,000 of the options vest in monthly increments over a period of one year from the grant date, and 20,000 of the options vest in monthly increments over a period of three years from the grant date. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 17:33 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantEmployee Stock Option (right to buy) · Derivative | 101,000 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001209191-22-037060 · doc4.xml · derivative · entry 1 Toernsen Monika Maria · CIK 0001873385 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,000 Underlying: Common Stock · 101,000 shares Expires 2032-06-12 F1 · derivative.exercise_date: The stock option vests as of 1/36 of the total shares monthly beginning on July 13, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 17:27 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantStock Option (right to buy) · Derivative | 101,000 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0001787297-22-000006 · primary_doc.xml · derivative · entry 1 Toernsen Monika Maria · CIK 0001873385 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,000 Underlying: Common Stock · 101,000 shares Expires 2032-02-09 F1 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning on March 10, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 18:54 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-047616 · doc4.xml · derivative · entry 2 Toernsen Monika Maria · CIK 0001873385 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: 1/4 of the RSUs will vest annually on September 15, 2022, and the remainder will vest as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date. F3 · derivative.expiration_date: 1/4 of the RSUs will vest annually on September 15, 2022, and the remainder will vest as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 18:54 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $13.04 | $0.00 |
DisclosureSEC source: 0001209191-21-047616 · doc4.xml · derivative · entry 1 Toernsen Monika Maria · CIK 0001873385 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-07-18 F1 · derivative.exercise_date: The option vests as to 25% of the total shares on July 19, 2022, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on July 19, 2024, subject to the Reporting Person's provision of service to the issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.